Where evidence meets experience.
Reach more participants, generate high-quality data, and simplify clinical trials, with a unified, easy-to-use platform.
One platform, from start to finish.
Onboard your participants
Total Consent Management incorporates easy-to-use tools like TeleVisit, remote scheduling, and compliant wet and dry signature to get your study started quickly and smoothly.
Take control of your trial
Keep your study on track and generate high-quality evidence with robust features like remote data collection, study notifications, participant reminders, and real-time reporting.
Data reporting and visualization
Oversight of your study data at your fingertips.
The Medable Effect
ROI for Phase III trials*
Rated DCT platform
Top Pharma customers
What makes us different
Best-in-class user experience
Informed by DCT experts, patient insights, and site feedback, the Medable platform accommodates the complex research landscape in an intuitive and simple user interface.
Designed to scale
Offered in over 60 countries and 120 languages, our cloud-agnostic, single API platform offers self-service build and a library of system integrations for maximum reach and scalability.
Extensive DCT network
Your study benefits from our extensive network of partners from retail pharmacy and site networks, data providers for RWE and LTFU, and direct-to-patient offering of connected sensors and home health providers.
Trusted by
The latest from Medable
Demo On Demand: eCOA+, patient & site experiences, and pulse oximeter sensor
VP of Solution Consulting, Jess Dolphi, showcases a few of the platform’s features, including site experience, patient experience, data and oversight dashboards, and a demonstration of connecting a pulse oximeter sensor for remote data capture.
U.S. Renal Care achieves 75% site adoption of eConsent with Medable
Medable’s Total Consent, used by U.S. Renal Care in top ten pharma-sponsored study, proved to be a flexible, fast, and efficient solution for the elderly renal care population.
The Definitive Guide to Digital Evidence Generation
According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than 12 billion dollars by 2030. Sparked by the COVID-19 pandemic of 2020, the rapid ascent of patient-centered technology and the digital and decentralized trials they’ve spawned has forever changed the landscape of clinical conduct. Sponsors are increasingly turning to DCT platforms in alignment with the rise of Life Science and Software-as-a-Service (SaaS) solutions. For those who haven't made the jump yet, there are many questions, including "What is a decentralized clinical trial?" Find out with this in-depth guide to decentralized clinical trials. Uncover how they work, their benefits, and how they transform clinical development.
New Medable Studio Empowers Sponsors to Launch eCOA Solutions into Clinical Trials with Unparalleled Control and Efficiency
Medable Studio for eCOA nowavailable; two top-10 pharma company early adopters
Medable Wins 2024 Prix Galien UK Award for Best Digital Health Solution
Medable today announced that its evidence generation platform was awarded “Best Digital Health Solution” from a field of 17 nominees at the Prix Galien UK Forum in London. This marks the second time Medable has won the Best Digital Health Solution award, first taking home the honor in 2023 at the Prix Galien US ceremony.
.jpg)
New Research from Partnership for Advancing Clinical Trials (PACT) Reveals Decentralized Clinical Trials (DCTs) Beat Timeline Expectations
Medable today announced that the Partnership for Advancing Clinical Trials (PACT) consortium in conjunction with the Tufts Center for the Study of Drug Development (CSDD) has produced compelling results from a new study.